Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III treat-through study of RO7790121 in moderately to severely active Crohn's disease
ChiCTR2500098333Phase 3Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of afimkibart in Crohn's disease (3 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Clinical remission at Week 52 and Endoscopic response at Week 52. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
afimkibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2500098333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098333.